Clinical trials: Resistant Arterial Hypertension
- Condition Resistant Arterial Hypertension
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Hypertension
Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients
This is a prospective, multicenter, feasibility study on the safety and efficacy of renal denervation in patients with resistant hypertension.
- Trial name
- EnligHTN-I (NCT01438229)
- Testing
- St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)
- Where
- 4 sites in Australia, Greece
- Volunteers
- 47 people
- Sponsor
- Abbott Medical Devices
Renal Artery Stenosis, Hypertension, Renovascular
Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension
The purpose of this trial is to test how well the iCAST™ RX Stent works in patients diagnosed with atherosclerotic renal artery stenosis and whether or not increased blood flow by the stent will help to control blood pressure.
- Trial name
- ARTISAN (NCT01673373)
- Testing
- iCAST™ Rx Stent System
- Where
- 12 sites in United States
- Volunteers
- 68 people
- Sponsor
- Atrium Medical Corporation
Hypertension With Metabolic Syndrome
Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
This proof of concept study is designed to evaluate the efficacy and safety of the combination therapy of aliskiren and ramipril as add-on to amlodipine in the treatment of patients with essential hypertension and metabolic…
- Trial name
- ALTO (NCT00542269)
- Testing
- Amlodipine, Aliskiren, Ramipril
- Where
- United Kingdom
- Volunteers
- 178 people
- Sponsor
- Novartis
Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
- Trial name
- Re-PHIRE (NCT05737940)
- Testing
- AZD3427
- Where
- 60 sites in United States, Austria and 12 more
- Volunteers
- 260 people
- Sponsor
- AstraZeneca
Resistant Hypertension
A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
The goal of this clinical trial is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure…
- Trial name
- PRECISION (NCT03541174)
- Testing
- Aprocitentan 12.5 mg, Aprocitentan 25 mg
- Where
- 159 sites in United States, Australia and 18 more
- Volunteers
- 730 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Resistant Hypertension
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs.
- Trial name
- Bax24 (NCT06168409)
- Testing
- Baxdrostat
- Where
- 102 sites in United States, Argentina and 20 more
- Volunteers
- 218 people
- Sponsor
- AstraZeneca
Resistant Hypertension
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
The purpose of this 20-week randomized double-blind study in patients with resistant hypertension (rHTN) is to evaluate the efficacy, safety, and tolerability, of different doses of XXB750 administered as subcutaneous (SC)…
- Trial name
- NCT05562934
- Testing
- XXB750 drug
- Where
- 78 sites in United States, Australia and 14 more
- Volunteers
- 189 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Concurrent Obesity
Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects
This study investigated the effects of LCZ696 on insulin sensitivity, lipolysis, and oxidative metabolism in obese hypertensive subjects.
- Trial name
- NCT01631864
- Testing
- LCZ696, amlodipine
- Where
- 3 sites in Germany, Netherlands
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Hyperkalemia, Resistant Hypertension
Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
The purpose of this study is to determine if patiromer treatment in chronic kidney disease (CKD) subjects receiving spironolactone for the treatment of resistant hypertension will result in more persistent use of spironolactone…
- Trial name
- AMBER (NCT03071263)
- Testing
- Patiromer, Spironolactone
- Where
- 40 sites in United States, Bulgaria and 7 more
- Volunteers
- 295 people
- Sponsor
- Relypsa, Inc.
Hypertension
Rheos® Pivotal Trial
The purpose of this clinical trial is to demonstrate the efficacy and safety of the Rheos system in subjects with hypertension that are resistant to treatment with at least three anti-hypertension agents, one of which is a…
- Trial name
- NCT00442286
- Testing
- Rheos® Baroreflex Hypertension System
- Where
- 44 sites in United States, Germany and 1 more
- Volunteers
- 591 people
- Sponsor
- CVRx, Inc.
Hypertension, Renal
RENABLATE Feasibility Study CS156 (EC12-02) Study of Catheter Based Renal Denervation to Treat Resistant Hypertension
The RENABLATE feasibility study is a prospective, multi-center, non-randomized feasibility study to evaluate the safety and effectiveness of the investigational multi-electrode ablation catheter and integrated ablation system to…
- Trial name
- NCT01756300
- Testing
- Celsius® ThermoCool® RD
- Volunteers
- 35 people
- Sponsor
- Biosense Webster, Inc.
Pulmonary Arterial Hypertension
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
The purpose of this study was to investigate the effects of QTI571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to participants with pulmonary arterial hypertension.
- Trial name
- NCT01392469
- Testing
- Imatinib, Sildenafil, Bosentan
- Where
- 11 sites in United States, Australia and 5 more
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Vascular Diseases
A Study of the ReCor Medical Paradise System in Clinical Hypertension
RADIANCE-HTN is a randomized, double-blind, sham controlled, 2-cohort study (TRIO and SOLO) designed to demonstrate efficacy and document the safety of the Paradise Renal Denervation System in two distinct populations of…
- Trial name
- RADIANCE-HTN (NCT02649426)
- Testing
- The Paradise® Renal Denervation Ultrasound System
- Where
- 49 sites in United States, Belgium and 5 more
- Volunteers
- 282 people
- Sponsor
- ReCor Medical, Inc.
Hypertension
Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter
The Study objective is to assess the performance of the Vessix V2 Renal Denervation System for the treatment of uncontrolled hypertension using an innovative percutaneous Radio Frequency (RF) balloon catheter renal denervation…
- Trial name
- REDUCE-HTN (NCT01541865)
- Testing
- Renal Denervation
- Where
- 26 sites in Australia, Austria and 6 more
- Volunteers
- 146 people
- Sponsor
- Boston Scientific Corporation
Hypertension
Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension
The primary objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40mg + amlodipine 10mg (T40/A10) or the fixed dose combination of telmisartan 80mg + amlodipine 10mg (T80/A10) is superior in…
- Trial name
- NCT00553267
- Testing
- fixed dose combination of telmisartan+amlodipine, amlodipine
- Where
- 97 sites in Australia, Austria and 12 more
- Volunteers
- 947 people
- Sponsor
- Boehringer Ingelheim
Hypertension
A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension
This study assessed the blood pressure effect, safety and tolerability of LCI699 compared to placebo and eplerenone in participants with resistant hypertension.
- Trial name
- NCT00817635
- Testing
- LCI699, Eplerenone
- Where
- 38 sites in United States, Iceland
- Volunteers
- 155 people
- Sponsor
- Novartis
Hypertension, Vascular Diseases
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent.
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Trial name
- RADIANCE-II (NCT03614260)
- Testing
- Paradise Renal Denervation System, Renal Angiogram
- Where
- 47 sites in United States, Belgium and 6 more
- Volunteers
- 224 people
- Sponsor
- ReCor Medical, Inc.
Uncontrolled Hypertension, Resistant Hypertension
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally…
- Trial name
- BaxHTN (NCT06034743)
- Testing
- Baxdrostat
- Where
- 263 sites in United States, Argentina and 27 more
- Volunteers
- 796 people
- Sponsor
- AstraZeneca
Hypertension
EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension
The purpose of the EnligHTN IV clinical investigation is to demonstrate the safety and effectiveness of the EnligHTN™ Renal Denervation System in the treatment of subjects with drug-resistant uncontrolled hypertension.
- Trial name
- EnligHTN-IV (NCT01903187)
- Testing
- EnligHTN Renal Denervation
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Abbott Medical Devices
Patients, Resistant Hypertension
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
The purpose of the present study was to determine whether LHW090 displays the clinical safety and efficacy profile to support further development in patients with resistant hypertension.
- Trial name
- NCT02515331
- Testing
- LHW090
- Where
- 16 sites in United States, Denmark and 4 more
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals